Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer's Disease
Editat de Adeboye Adejareen Limba Engleză Hardback – 4 oct 2016
The book explores diagnosis, epidemiology, drug discovery strategies, current therapeutics, and much more to provide a holistic approach to the discovery, development, and treatment of Alzheimer’s Disease. Through its coverage of the latest research in targeted drug design, preclinical studies, and mouse and rat models, the book is a must-have resource for all pharmaceutical scientists, pharmacologists, neuroscientists, and clinical researchers working in this area. It illustrates why these drugs tend to fail at the clinical stage, and examines Alzheimer’s Disease within the overall context of improving the drug discovery process for the treatment of other neurodegenerative disorders.
- Provides a compilation of chemical considerations required in drug discovery for the treatment of neurodegenerative disorders
- Examines different classes of compounds currently being used in discovery and development stages
- Explores in vitro and in vivo models with respect to their ability to translate these models to human conditions
- Distills the most significant information across multiple areas of Alzheimer’s disease research to provide a single, comprehensive, and balanced resource
Preț: 639.72 lei
Preț vechi: 854.01 lei
-25% Nou
Puncte Express: 960
Preț estimativ în valută:
122.47€ • 127.78$ • 102.66£
122.47€ • 127.78$ • 102.66£
Carte tipărită la comandă
Livrare economică 06-20 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780128028100
ISBN-10: 0128028106
Pagini: 316
Ilustrații: black & white illustrations
Dimensiuni: 191 x 235 x 24 mm
Greutate: 0.75 kg
Editura: ELSEVIER SCIENCE
ISBN-10: 0128028106
Pagini: 316
Ilustrații: black & white illustrations
Dimensiuni: 191 x 235 x 24 mm
Greutate: 0.75 kg
Editura: ELSEVIER SCIENCE
Public țintă
Professionals involved in the drug discovery process, whether in academia, research institutes or the pharmaceutical industry. This includes scientists who are involved in drug design to those involved in clinical trials.Cuprins
1. General description of neurodegenerative disorders
2. Alzheimer’s disease diagnosis
3. National plan and resources to address Alzheimer’s disease
4. Current Medications for Treatment of Alzheimer's Disease: Acetylcholine esterase inhibitors and NMDA receptor antagonist
5. Physicochemical properties for potential AD drugs
6. Receptor approaches
7. Amyloid hypothesis
8. Tau proteins
9. Cholesterol and fat metabolism
10. Energy Metabolism
11. Simple in vivo models of Neurodegeneration (C. Elegans, fruitfly, and similar models)
12. Rodent Models
13. Clinical Trials
14. Non-pharmacologic Treatment Approaches
2. Alzheimer’s disease diagnosis
3. National plan and resources to address Alzheimer’s disease
4. Current Medications for Treatment of Alzheimer's Disease: Acetylcholine esterase inhibitors and NMDA receptor antagonist
5. Physicochemical properties for potential AD drugs
6. Receptor approaches
7. Amyloid hypothesis
8. Tau proteins
9. Cholesterol and fat metabolism
10. Energy Metabolism
11. Simple in vivo models of Neurodegeneration (C. Elegans, fruitfly, and similar models)
12. Rodent Models
13. Clinical Trials
14. Non-pharmacologic Treatment Approaches